Skip to main content

Scar Prevention

3
Pipeline Programs
2
Companies
4
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
3
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Pfizer
PfizerNEW YORK, NY
3 programs
3
EXC 001Phase 21 trial
EXC 001Phase 21 trial
EXC 001Phase 21 trial
Active Trials
NCT01037413Completed25Est. Apr 2010
NCT01038297Completed30Est. Jul 2010
NCT01037985Completed41Est. Sep 2010
Lumenis
LumenisAustralia - Chatswood
1 program
Lumenis UltraPulse single fractional CO2 laser treatment thin skinN/A1 trial
Active Trials
NCT01826942Terminated10Est. Mar 2013

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
PfizerEXC 001
PfizerEXC 001
PfizerEXC 001
LumenisLumenis UltraPulse single fractional CO2 laser treatment thin skin

Clinical Trials (4)

Total enrollment: 106 patients across 4 trials

NCT01037413PfizerEXC 001

Safety and Efficacy Study of EXC 001 to Improve the Appearance of Scars From Prior Breast Surgery

Start: Dec 2009Est. completion: Apr 201025 patients
Phase 2Completed
NCT01037985PfizerEXC 001

Safety and Efficacy Study of EXC 001 to Improve the Appearance of Scars in Subjects Undergoing Elective Abdominoplasty

Start: Dec 2009Est. completion: Sep 201041 patients
Phase 2Completed
NCT01038297PfizerEXC 001

Safety and Efficacy Study of Different Dose Levels of EXC 001 to Improve the Appearance of Scars in Subjects Undergoing Elective Abdominoplasty

Start: Dec 2009Est. completion: Jul 201030 patients
Phase 2Completed
NCT01826942LumenisLumenis UltraPulse single fractional CO2 laser treatment thin skin

Scar Prevention Using Fractional Carbon Dioxide Laser Treatment

Start: Jan 2013Est. completion: Mar 201310 patients
N/ATerminated

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.